Is now the right time to invest in China? If yes, what kind of startups are the best bet? What is considered an innovative business model in current China? These are the questions lively discussed at the 2016 China Healthcare Investment Conference (CHIC), which was held in Shanghai in late March, reports The Pharma Letter’s local correspondent Wang Fangqing.
The Chinese government is keen on attracting International investments, said Bi Jiyao, a director at China’s National Development and Reform Commission (NDRC). “China as a fast aging country has huge demand for healthcare products and services, a major part of which are high quality and novel drugs. But under China’s current system, it’s difficult for a startup to get funded. We hope international investors will be able to catch the opportunity,” Mr Bi said at CHIC.
The Chinese government underscores innovation in the 13th five-year plan (2015 to 2020) for the pharma industry, aiming to turn China from a drug manufacturer to a drug innovator. To encourage innovation, China recently changed some polices to speed up its notoriously slow approval process for Investigational New Drug (IND) and New Drug Applications (NDA), and is in progress to upgrade the drug list covered by the national Medicare program, which has remained the same for the past seven years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze